title: American Society of Clinical Oncology 2011 CNS tumors update.
abstract: A number of important studies were presented at the CNS tumors section of the 2011 American Society of Clinical Oncology Annual Meeting. There was particular interest in RTOG 0525, a Phase III study of newly diagnosed glioblastoma treated with different schedules of temozolomide. Prognostic factors for response, survival and chemotherapy-related toxicity in primary CNS lymphoma from the German randomized Phase III trial in newly diagnosed primary CNS lymphoma were also presented.
authors: Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73 Cleveland, OH 44195, USA. ahluwam@ccf.org
authors: Manmeet S
authors: MS
authors: Ahluwalia
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D000077204:Temozolomide
chemical_list: D000970:Antineoplastic Agents; D003606:Dacarbazine; D000077204:Temozolomide